Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20178633 | 0.80 | HTR2A (0.41) | HTR2AHTR2CHTR2BKDM1AAR | |
| SCHEMBL20178676 | 0.77 | HTR2A (0.43) | HTR2AHTR2CHTR2BKIF11 | |
| SCHEMBL20173787 | 0.76 | HTR2A (0.44) | HTR2AHTR2CHTR2BKDM1AAR | |
| SCHEMBL8262221 | 0.71 | AR (0.37) | HTR2AHTR2CHTR2BKDM1AAR | |
| SCHEMBL3874950 | 0.71 | ALDH1A1 (0.36) | HTR2AHTR2CHTR2BKDM1AAR | |
| SCHEMBL15850523 | 0.69 | KIF11 (0.44) | KDM1AARGPR3KIF11 | |
| SCHEMBL31327518 | 0.65 | KIF11 (0.41) | HTR2AHTR2CHTR2BKDM1AAR | |
| SCHEMBL8975074 | 0.65 | KIF11 (0.41) | HTR2AHTR2CHTR2BKDM1AAR | |
| Trifluoroacetic Acid SCHEMBL3880387 | 0.62 | AR (0.35) | HTR2AHTR2CHTR2BKDM1AAR | |
| SCHEMBL14525575 | 0.62 | TRPV1 (0.37) | HTR2AHTR2CHTR2BKDM1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | HTR2A 3895/4885HTR2C 2204/4885HTR2B 2890/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | HTR2A 3895/4885HTR2C 2204/4885HTR2B 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.